Camber Launches Generic Mepron®
Piscataway, NJ, October 12, 2018– Camber Pharmaceuticals is pleased to announce the addition of Atovaquone Oral Solution to our growing portfolio of products.
Atovaquone Oral Solution is the generic version of Mepron ®. Atovaquone is used to treat or prevent pneumonia caused by a fungal infection called Pneumocystis carinii.
Atovaquone Oral Solution is available in 750 mg/5 mL bottles.
Camber’s commitment to its customers is to bring the highest quality generic pharmaceuticals to the market and provide a level of excellence in service, supply and affordability.
If you would like more information about this topic, please contact Kirk Hessels at 732.529.0430 or email at [email protected].
Recent articles
- Camber Launches Abacavir and Lamivudine Tablets, USP
- Camber’s Parent Company, Hetero, Partners with the Gates Foundation to Supply Generic Lenacapavir for HIV Prevention
- Camber Adds 800 mg Darunavir Tablets to Product Family
- Camber Expands Portfolio with 10 New Generic Drug Launches in Q3 2025
- Camber Launches Indomethacin Suppositories
- Camber Launches Voriconazole for Injection





